Related Experiment Video
Updated: Aug 19, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Steven F Kendell1, John H Krystal, Gerrard Sanacora
1Yale University School of Medicine, Department of Psychiatry, 333 Cedar Street, New Haven, CT 06510, USA.
Abstract:
Advances made in diverse areas of neuroscience suggest that neurotransmitter systems, additional to the monoaminergic, contribute to the pathophysiology of mood disorders. This ever accruing body of preclinical and clinical research is providing increased recognition of the contribution made by amino acid neurotransmitters to the neurobiology of mood disorders. This review examines evidence supporting the role of GABA and glutamate in these processes and explores the potential to target these systems in the development of novel compounds; the viability of these agents for treatment-related co-morbidities will also be considered.
Related Concept Videos
G-protein Coupled Receptors
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists
Ligand-Gated Ion Channel Receptor: Gating Mechanism
